Hospital

Data from a phase 1/2 trial revealed that CRISPR–Cas9–edited donor stem cell transplants lacking CD33 enabled rapid engraftment and allowed posttransplant gemtuzumab ozogamicin maintenance in high-risk patients with AML/MDS without prolonged hematologic toxicity.

A novel urine-based test outperformed mpMRI in detecting prostate cancer progression and may help reduce unnecessary biopsies.

Emerging evidence supports the use of psilocybin in palliative care, yet Schedule I status uniquely limits access outside of clinical trials in the US.

FDA approval brings the first all-oral AML combination therapy, decitabine/cedazuridine with venetoclax, for older or unfit patients, cutting clinic visits.

Phase 1b data show zongertinib delivers durable first-line responses in HER2-mutant NSCLC, including brain metastases, with manageable safety.

The commissioner's sudden departure leaves the agency navigating a crowded agenda of unresolved policy questions—many with direct implications for pharmacists and their patients.

Newborn vitamin K shot refusals rise, boosting bleeding risk; learn neonatal safety facts and how the vitamin K shot prevents deadly VKDB.

As medetomidine rapidly displaces xylazine as a fentanyl adulterant, pharmacists must recognize its distinct toxidrome, understand why naloxone alone is insufficient, and support updated harm reduction strategies in an increasingly complex overdose landscape.

Pharmacy Times interviews Benjamin Kematick, PhD, BCACP, BCPMP, and explores the safety profile of Levorphanol compared with methadone, including potential reductions in risks such as accumulation, QT prolongation, and drug interactions, as well as its implications for clinical workflows and the pharmacist’s role in supporting safe opioid rotation, monitoring, and patient counseling.

Pharmacy Times interviews Benjamin Kematick, PhD, BCACP, BCPMP, and examines how levorphanol compares to methadone in pharmacology and clinical efficacy, as well as the key evidence supporting its use and the practical barriers clinicians face when transitioning between the two agents in complex pain management.

A new JAMA study links GLP-1s like Wegovy, Ozempic, Zepbound, and Mounjaro to better breast cancer survival, lower recurrence, and weight loss benefits.

Recent randomized trials and CDC guidance support doxycycline postexposure prophylaxis as a targeted strategy to reduce bacterial STIs in high-risk populations.

The study authors also emphasized that close monitoring during gabapentinoid treatment is necessary, and concomitant use with opioids or benzodiazepines should be avoided.

Rhonda Monroe discusses her harrowing journey as a 3-time heart attack and stroke survivor, highlighting the critical importance of patient self-advocacy.

Makary's 13-month tenure ends after clashes with the Trump administration over flavored vape approvals, mifepristone policy, and broader agency management.

Inflammation fuels residual ASCVD risk; survey reveals hs-CRP testing gaps, persistent angina, and new therapies for cardiovascular health.

Pharmacy Times interviews Benjamin Kematick, PhD, BCACP, BCPMP, and explores the clinical scenarios and patient populations that prompted the consideration of levorphanol as a methadone-sparing option in complex pain management.

Hirsch shows how mentorship and networks shape a pharmacist-scientist, driving infectious disease research and fosfomycin breakthroughs.

A study finds that nearly half of older adults with mNSCLC do not receive treatment despite major advances in immunotherapy and targeted therapies that can improve survival and quality of life.

The ACACIA-HCM trial marks the first time a therapy has shown statistically significant improvements in exercise capacity and symptom burden in patients with non-obstructive hypertrophic cardiomyopathy.

Health systems are being pushed to fundamentally rethink how to support medication safety, regulatory compliance, and patient care with fewer resources.

Ketamine, an NMDA receptor antagonist, is increasingly being used in low-dose infusions as a multimodal, opioid-sparing strategy for patients with refractory acute and chronic pain.

Outpatient infusion and specialty pharmacy pharmacists drive safe, cost-effective oncology and chronic-care expansion, from biosimilars to community access

See how pharmacists turn pharmacogenomic results into safer prescribing—overcoming reimbursement, EHR, and equity barriers to scale testing in community pharmacies.

Phase 3 findings from the VIKTORIA-1 trial demonstrated clinically meaningful progression-free survival improvements with gedatolisib-based regimens in patients with PIK3CA-mutant HR+/HER2– advanced breast cancer.

Metabolic dysfunction-associated steatotic liver disease (MASLD) remains largely underdiagnosed and asymptomatic, creating major opportunities for pharmacists to drive early identification, lifestyle intervention, and metabolic risk management.

This approval marks the first high-efficacy B-cell depletion therapy approved for pediatric patients 10 years and older.

Treatment with zenocutuzumab-zbco led to an overall response rate of 36.8% for a duration ranging from 2.8 to 12.9 months.